Tech Company Financing Transactions
PhotoPharmics Funding Round
On 4/18/2025, PhotoPharmics raised $6 million in Series B funding from Kickstart Fund.
Transaction Overview
Company Name
Announced On
4/18/2025
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series B
Investors
Kickstart Fund (Lead Investor)
Proceeds Purpose
The additional capital will also support pre-commercialization efforts, including regulatory prep, strategic partnerships, and patient access strategies.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
3451 North Triumph Boulevard 201
Lehi, UT 84043
USA
Lehi, UT 84043
USA
Phone
Website
Email Address
Overview
Specialized phototherapy addresses both motor and non-motor symptoms. Over 11 million people worldwide live with Parkinson's disease (PD), a number that is projected to double over the next 20 years. As with so many other neurodegenerative diseases, there have been no major breakthroughs in Parkinson's disease in decades. Our personalized at-home device promises to be one of the most significant therapeutic breakthroughs in Parkinson's disease in decades. We have seen large improvements in our proof-of-concept studies -- especially in addressing major unmet needs in Parkinson's. We are initiating a pivotal trial of our key product, Celeste® specialized phototherapy, to confirm safety and sustained efficacy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kent Savage
Browse more venture capital transactions:
Prev: 4/18/2025: Yarbo venture capital transaction
Next: 4/18/2025: Neutrl venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs